Earnings Analysis July 29, 2026

Ionis Pharmaceuticals ($IONS) Q2 2026 Earnings Analysis — Revenue Significantly Beats Expectations, Full-Year Guidance Maintained

Earnings Scorecard

Revenue: $268 million (+56% YoY excluding one-time items; estimate $190 million) ✅ Beat

EPS: GAAP -$0.69 (adjusted per-share figure not provided; not directly comparable to adjusted estimate of -$0.88 due to differing bases)

Guidance: Maintained — on track to meet 2026 full-year financial guidance, 2028 cash flow breakeven target reaffirmed

Stock Reaction: After-hours +1.54% ($56.15) — as of 07-29 20:35 KST

The Positives

Revenue beat: Q2 revenue of $268 million meaningfully topped the $190 million estimate

DAWNZERA growth: U.S. net revenue of $26 million, up 63% sequentially

Guidance & cash: Full-year guidance on track; quarter-end cash and short-term investments of $2.1 billion

Q2 total revenue of $268 million declined from $452 million a year earlier, but excluding a one-time $280 million sapablursen upfront payment recognized in the prior-year quarter, revenue grew 56%. Commercial revenue rose 15% YoY to $119 million, and R&D collaboration revenue was also supported by milestone payments tied to progress across multiple partner programs.

Among self-commercialized products, DAWNZERA (indicated for hereditary angioedema prevention) stood out. U.S. net revenue reached $26 million in Q2 and $42 million in the first half, and the company maintained its full-year target of $110–$120 million. TRYNGOLZA, approved at the end of June for severe hypertriglyceridemia, was highlighted for its early launch momentum. Meanwhile, zilganersen (Alexander disease candidate) has a PDUFA target date of September 22, and bepirovirsen (chronic hepatitis B candidate) is awaiting an October 26 decision.

Citing first-half self-commercialization performance and the second-half outlook, the CFO reaffirmed 2026 financial guidance and the 2028 cash flow breakeven target. Quarter-end cash and short-term investments stood at $2.1 billion — lower than year-end due to convertible bond redemptions and similar items, but presented as sufficient runway to continue investing in the in-house pipeline.

The Negatives

TRYNGOLZA quarterly revenue: U.S. net revenue of $5 million, down from $19 million a year earlier

Cardiomyopathy Phase 3 failure: Eplontersen Phase 3 in cardiac indication missed the primary endpoint in the overall population

Cost & loss expansion: Higher operating expenses from launch/pre-launch investments; GAAP operating loss of $102 million

TRYNGOLZA U.S. net revenue came in at just $5 million in Q2. Familial chylomicronemia syndrome demand continued, but a net price reduction effective April 1 was reflected in the figures, and the severe hypertriglyceridemia indication approval arrived only at the end of June, limiting its contribution in the quarter. The company held to its full-year product revenue target of $100–$110 million, but how quickly the new indication translates into actual revenue needs to be confirmed in the second half.

On the partner side, eplontersen ( Wainua ) Phase 3 CARDIO-TTRansform study in transthyretin amyloid cardiomyopathy failed to meet the primary composite endpoint in the overall patient population. The company noted nominal significance in a pre-specified monotherapy subgroup and a favorable safety profile, but expectations for a cardiac label expansion have been dialed back. Detailed results are slated for presentation at the European Society of Cardiology meeting in August.

Operating expenses increased year over year on TRYNGOLZA and DAWNZERA commercialization investments and zilganersen launch preparation, resulting in a GAAP operating loss of $102 million and a net loss of $115 million. Management said full-year expense growth is tracking to a low-double-digit percentage range, but if commercial performance fails to outpace costs while the company remains in a loss position, the timeline to profitability could slip.

What Management Said

Management characterized the first half as a period in which expansion of self-commercialized product revenue, partner R&D revenue, and investment in the wholly owned pipeline all advanced in parallel. The CEO highlighted positive early launch momentum following the severe hypertriglyceridemia approval of TRYNGOLZA, and emphasized that the second half carries a cluster of milestones, including the potential zilganersen approval, pelacarsen cardiovascular outcomes study readout, and bepirovirsen global launch.

Even after the eplontersen cardiac Phase 3 result, the CFO framed the message around first-half execution and second-half visibility, reiterating that the path to 2026 full-year guidance and the 2028 cash flow breakeven target remains intact. The tone leaned more on the commercialization trajectory and upcoming regulatory/clinical calendar than on the quarter's numbers.

Market Reaction and What to Watch

The revenue beat and reaffirmation of full-year guidance and cash flow targets are being read as relief factors. DAWNZERA growth, the new TRYNGOLZA indication launch, and second-half approval milestones sustain the commercialization narrative. On the other hand, TRYNGOLZA's quarterly revenue remains small and the overall-population failure of the eplontersen cardiac Phase 3 lowers expectations. The modest after-hours gain reflects the beat and maintained guidance, but leaves pipeline risks on the table — a balanced reaction overall.

Track how quickly prescriptions and revenue accelerate for TRYNGOLZA in severe hypertriglyceridemia from Q3 onward.

Watch the September PDUFA date for zilganersen and the October PDUFA date for bepirovirsen, along with whether launch readiness stays on schedule.

Review the detailed eplontersen cardiac Phase 3 data at the European Society of Cardiology meeting in August and the subsequent strategy from the company and its partner.